Application No.: 10/575,096

**AMENDMENTS TO THE CLAIMS** 

This listing of claims will replace all prior versions and listings of claims in the

application:

**LISTING OF CLAIMS:** 

1. (currently amended): A process for producing an antibody composition using a

cell, which comprises using a cell into which a double-stranded RNA comprising an RNA

selected from the following (a) or (b) and its complementary RNA is introduced:

(a) an RNA comprising the nucleotide sequence represented by any one of SEQ ID

NOs:9 to 3011;

(b) an RNA consisting of a nucleotide sequence in which one or several nucleotide(s)

is/are deleted, substituted, inserted and/or added in having 80% or more homology to the

nucleotide sequence represented by any one of SEQ ID NOs:9 to 3011 and having activity of

suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-

position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-

bond in a complex type N-glycoside-linked sugar chain.

**2. (original):** The process according to claim 1, wherein the enzyme relating to the

modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-

acetylglucosamine in the reducing end through  $\alpha$ -bond in the complex type N-glycoside-linked

sugar chain is α1,6-fucosyltransferase.

3. (currently amended): The process according to claim 2, wherein the  $\alpha$ 1,6-

fucosyltransferase is a protein encoded by a DNA selected from the group consisting of the

following (a) to and (hb):

(a) a DNA comprising the nucleotide sequence represented by of SEQ ID NO:1; and

2

Application No.: 10/575,096

(b) a DNA comprising the nucleotide sequence represented by SEQ ID NO:2;

(c) a DNA comprising the nucleotide sequence represented by SEQ ID NO:3;

(d) a DNA comprising the nucleotide sequence represented by SEQ ID NO:4;

(e)—a DNA which hybridizes with a DNA consisting of to the nucleotide sequence
that is entirely complementary to represented by SEQ ID NO:1 under stringent conditions and

encodes a protein having α1,6-fucosyltransferase activity;

(f) a DNA which hybridizes with a DNA consisting of the nucleotide sequence

represented by SEQ ID NO:2 under stringent conditions and encodes a protein having α1,6-

fucosyltransferase activity;

(g) a DNA which hybridizes with a DNA consisting of the nucleotide sequence

represented by SEQ ID NO:3 under stringent conditions and encodes a protein having α1,6-

fucosyltransferase activity;

(h) a DNA which hybridizes with a DNA consisting of the nucleotide sequence

represented by SEQ ID NO:4 under stringent conditions and encodes a protein having α1,6-

fucosyltransferase activity.

4. (currently amended): The process according to claim 2, wherein the  $\alpha 1,6$ -

fucosyltransferase is a protein selected from the group consisting of the following (a) to-and (4b):

(a) a protein comprising the amino acid sequence represented by of SEQ ID NO:5;

and

(b) a protein comprising the amino acid sequence represented by SEQ ID NO:6;

(c) a protein comprising the amino acid sequence represented by SEQ ID NO:7;

(d) a protein comprising the amino acid sequence represented by SEQ ID NO:8;

3

Application No.: 10/575,096

(e) a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:5 and having α1,6-fucosyltransferase activity;

- (f) a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:6 and having α1,6-fucosyltransferase activity;
- (g) a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:7 and having α1,6-fucosyltransferase activity;
- (h) a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:8 and having α1,6-fucosyltransferase activity;
- (i)—a protein consisting of an amino acid sequence which has 80% or more homology to the amino acid sequence represented byof SEQ ID NO:5 and having α1,6-fucosyltransferase activity;
- (j) a protein consisting of an amino acid sequence which has 80% or more homology to the amino acid sequence represented by SEQ ID NO:6 and having α1,6-fucosyltransferase activity;
- (k) a protein consisting of an amino acid sequence which has 80% or more homology to the amino acid sequence represented by SEQ ID NO:7 and having α1,6-fucosyltransferase activity;

Application No.: 10/575,096

(l) a protein consisting of an amino acid sequence which has 80% or more homology to the amino acid sequence represented by SEQ ID NO:8 and having  $\alpha$ 1,6-fucosyltransferase activity.

- 5. (previously presented): The process according to claim 1, wherein the cell into which the RNA having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is introduced is a cell which is resistant to a lectin which recognizes a sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in an N-glycoside-linked sugar chain.
- 6. (currently amended): The process according to claim 5, wherein the cell is resistant to at least one lectin selected from the group consisting of the following (a) to (d):
  - (a)—a Lens culinaris lectin;
  - (b) a Pisum sativum lectin;
  - (c) a Vicia faba lectin;
  - (d) an Aleuria aurantia lectin.
- 7. (currently amended): The process according to claim 1, wherein the cell is selected from the group consisting of a yeast cell, an animal cell, an insect cell and a plant cell.
- 8. (currently amended): The process according to claim 1, wherein the cell is a cell selected from the group consisting of the following (a) to (i):
  - (a)—a CHO cell derived from Chinese hamster ovary tissue;
  - (b) a rat myeloma cell line YB2/3HL.P2.G11.16Ag.20 cell;
  - (c) a mouse myeloma cell line NS0 cell;

Application No.: 10/575,096

(d) a mouse myeloma cell line SP2/0-Ag14 cell;

(e) a BHK cell derived from Syrian hamster kidney tissue;

(f) an antibody-producing hybridoma cell;

(g) a human leukemia cell line Namalwa cell;

(h) an embryonic stem cell;

(i) a fertilized egg cell.

9. (previously presented): The process according to claim 1, wherein the cell is a transformant into which a gene encoding an antibody molecule is introduced.

10. (original): The process according to claim 9, wherein the antibody molecule is selected from the group consisting of the following (a) to (d):

- (a) a human antibody;
- (b) a humanized antibody;
- (c) an antibody fragment comprising the Fc region of (a) or (b);
- (d) a fusion protein comprising the Fc region of (a) or (b).
- 11. (previously presented): The process according to claim 9, wherein the antibody molecule belongs to an IgG class.
- 12. (currently amended): The process according to claim 1, wherein the antibody composition is an antibody composition having higher antibody-dependent cell-mediated cytotoxic activity than an antibody composition produced by a parent cell into which a double-stranded RNA comprising an RNA selected from the following (a) or (b) and its complementary RNA is not introduced:
- (a) an RNA comprising the nucleotide sequence <del>represented by any one</del> of SEQ ID NOs:9 to 3011;

Application No.: 10/575,096

(b) an RNA consisting of a nucleotide sequence in which one or several nucleotide(s) is/are deleted, substituted, inserted and/or added inhaving 80% or more homology to the nucleotide sequence represented by any one of SEQ ID NOs:9 to 3011 and having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain.

- 13. (original): The process according to claim 12, wherein the antibody composition having higher antibody-dependent cell-mediated cytotoxic activity is an antibody composition which comprises antibody molecules having complex type N-glycoside-linked sugar chains in the Fc region, and in which a ratio of sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains among the complex type N-glycoside-linked sugar chains is higher than that of an antibody composition produced by the parent cell.
- 14. (original): The process according to claim 13, wherein the complex type N-glycoside-linked sugar chains are sugar chains in which 1-position of fucose is not bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in the sugar chains.
- 15. (previously presented): The process according to claim 12, wherein the antibody composition having higher antibody-dependent cell-mediated cytotoxic activity is an antibody composition which comprises antibody molecules having complex type N-glycoside-linked sugar chains in the Fc region, and in which the ratio of sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains among the complex type N-glycoside-linked sugar chains is 20% or more.
- 16. (previously presented): The process according to claim 1, wherein the antibody composition having higher antibody-dependent cell-mediated cytotoxic activity is an antibody

Application No.: 10/575,096

composition which comprises antibody molecules having complex type N-glycoside-linked sugar chains in the Fc region, and in which the complex type N-glycoside-linked sugar chains are sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing end.

- 17. (withdrawn): A cell into which an RNA capable of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is introduced, and which is used in the process according to claim 1.
- 18. (withdrawn): The cell according to claim 17, wherein the enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is  $\alpha$ 1,6-fucosyltransferase.
- 19. (withdrawn): A cell in which an RNA selected from RNAs of the group consisting of the nucleotide sequences represented by any one of SEQ ID NOs:9 to 30 is introduced or expressed.
- **20. (withdrawn):** A double-stranded RNA consisting of an RNA selected from the following (a) or (b) and its complementary RNA:
- (a) an RNA comprising the nucleotide sequence represented by any one of SEQ ID NOs:9 to 30;
- (b) an RNA consisting of a nucleotide sequence in which one or several nucleotide(s) is/are deleted, substituted, inserted and/or added in the nucleotide sequence represented by any one of SEQ ID NOs:9 to 30 and having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position

Application No.: 10/575,096

of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain.

- **21. (withdrawn):** A DNA corresponding to the RNA described in claim 20 and a complementary DNA to the DNA.
- **22. (withdrawn):** A recombinant DNA which is obtainable by introducing a DNA corresponding to the RNA described in claim 20 and a complementary DNA to the DNA into a vector.
- **23. (withdrawn):** The recombinant DNA according to claim 22, which expresses the double-stranded RNA consisting of an RNA selected from the following (a) or (b) and its complementary RNA:
- (a) an RNA comprising the nucleotide sequence represented by any one of SEQ ID NOs:9 to 30;
- (b) an RNA consisting of a nucleotide sequence in which one or several nucleotide(s) is/are deleted, substituted, inserted and/or added in the nucleotide sequence represented by any one of SEQ ID NOs:9 to 30 and having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain.
- **24. (withdrawn):** A transformant which is obtainable by introducing the recombinant DNA according to claim 22 into a cell.
- 25. (withdrawn): A method for constructing a cell which is resistant to a lectin which recognizes a sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked

Application No.: 10/575,096

sugar chain, which comprises introducing or expressing the double-stranded RNA described in claim 20 in a cell.

**26. (withdrawn):** The method according to claim 25, wherein the cell which is resistant to a lectin which recognizes a sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is resistant to at least one lectin selected from the group consisting of the following (a) to (d):

- (a) a Lens culinaris lectin;
- (b) a *Pisum sativum* lectin;
- (c) a Vicia faba lectin;
- (d) an Aleuria aurantia lectin.
- 27. (withdrawn): A method for suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain, which comprises using an RNA selected from RNAs of the group consisting of the nucleotide sequences of any one of SEQ ID NOs:9 to 30.
- 28. (withdrawn): The method according to claim 27, wherein the enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through  $\alpha$ -bond in a complex type N-glycoside-linked sugar chain is  $\alpha$ 1,6-fucosyltransferase.

10